Speciality
Spotlight

 




 


Endocrinology


   

  




Osteoporosis

 


  • Fosamax
    for male osteoporosis

    SCRIP
    No.2575, Sept.15, 2000,

     

    Evidence
    has now become available from a 2-year study of
    alendronate, in the treatment of men with
    osteoporosis.  Results
    are published in the New
    England Journal of Medicine, August 31, 2000, pg.604. 
    On the basis of this publication, Merck has
    filed for this new indication in the USA and the EU
    and approvals are expected.

     

    The
    incidence of osteoporosis in men is rising and
    possibly male osteoporosis may become a major
    indication for alendronate.

      

 



 

 

Speciality Spotlight

 

 
Endocrinology
   

  

Osteoporosis
 

  • Fosamax for male osteoporosis
    SCRIP No.2575, Sept.15, 2000,
     
    Evidence has now become available from a 2-year study of alendronate, in the treatment of men with osteoporosis.  Results are published in the New England Journal of Medicine, August 31, 2000, pg.604.  On the basis of this publication, Merck has filed for this new indication in the USA and the EU and approvals are expected.
     
    The incidence of osteoporosis in men is rising and possibly male osteoporosis may become a major indication for alendronate.
      

 

 

By |2022-07-20T16:42:13+00:00July 20, 2022|Uncategorized|Comments Off on Osteoporosis

About the Author: